

Writing a paper: Introduction

Example: Recurrent tuberculosis

By prof.S.G.Hinderaker
(Courtesy of A.D.Harries)



TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2000) 94, 247-249

Relapse and recurrent tuberculosis in the context of a National Tuberculosis Control Programme

A. D. Harries¹, N. J. Hargreaves^{2,3}, J. H. Kwanjama¹ and F. M. L. Salaniponi¹ ¹National Tuberculosis Control Programme, Ministry of Health, P.O. Box 30377, Capital City, Lilongwe 3, Malawi; ²Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK

Courtesy of AD Harries

Before you start

- What is the **main** message?
- What is new?
- Which journal?
- Which audience?
- Which format?
 - Original article
 - Short communication
 - Review

3

Introduction

- Set the scene - What is the general problem?
- Specific question to be addressed
- What has been done before - the latest research
- Don't over-cite
- Problems with previous research
- What is still unknown? Gaps?
- What's new? - Marketing!
- Conclude intro with objectives – 1-2 sentences

4

Courtesy of T.Reid

INTRODUCTION: Outline

- Describe the present situation and the background to why you have carried out this study
- Avoid a long comprehensive review
- State clearly the aim of the study



ANNUAL TB RECURRENCE

	<u>HIV+ve</u>	<u>HIV-ve</u>	
Zaire	18%	6%	(Perriens et al 1991)
Kenya	17%	0.5%	(Hawken et al 1993)
Zambia	22%	6%	(Elliott et al 1995)
S.Africa	16%	6%	(Sonnenberg et al 2001)




PREVIOUS STUDIES

These studies have found that recurrence is increased in patients who were infected with HIV

Therefore where HIV-infection rates are high we should find increased recurrence rates of TB



% Patients with Relapse sm+ve PTB in Malawi



1987 - 1999

No recurrent cases of smear-negative PTB or EPTB recorded in TB registers



HIV among TB patients in Malawi

<u>Year</u>	<u>Site</u>	<u>No. TB</u>	<u>% HIV+ve</u>
1986	Zomba	125	26
1993	Mzuzu	167	67
1994	Blantyre	665	75
1995	Zomba	793	77
2000	Malawi	512	77



THE PROBLEM

- In Malawi, despite rising HIV-prevalence rates, relapse TB cases have stayed the same and there have been no registered cases of recurrent smear-negative PTB or EPTB
- Previously treated patients need a stronger regimen and must be identified
- Maybe the NTP is missing recurrent TB under routine programme conditions



AIM OF THE STUDY

The aim of the study was to determine whether patients with relapse smear+ve PTB and recurrent smear-negative PTB / EPTB were being missed under routine programme conditions in Malawi



INTRODUCTION

Setting the scene (1)

- Africa is currently faced by two intersecting epidemics – HIV and tuberculosis (TB)
- This has resulted in an tremendous increase in case notifications, with increasing morbidity and mortality in HIV-infected TB patients.
- An increase in recurrent TB also appears to be a problem

13

INTRODUCTION:

Previous studies (2)

Previous studies have found that recurrence is increased in patients who were infected with HIV

Therefore where HIV-infection rates are high we should find increased recurrence rates of TB

14

INTRODUCTION:

The problem and study rationale (3)

- In Malawi, despite rising HIV-prevalence rates, relapse TB cases have stayed the same and there have been no registered cases of recurrent smear-negative PTB or EPTB
- Our hypothesis is that the NTP is missing recurrent TB under routine program conditions

15

INTRODUCTION:

The aim of the study (4)

This study was undertaken to determine whether patients with relapse smear-positive Pulmonary TB and recurrent smear-negative TB are being incorrectly registered as “new” TB under routine programme conditions

16

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2001) 95, 503–504

Short Report

Recurrent tuberculosis in Malawi: improved diagnosis and management following operational research

A. D. Harries and F. M. L. Salaniponi *National Tuberculosis Control Programme, Ministry of Health, P.O. Box 30377, Capital City, Lilongwe 3, Malawi*

Keywords: tuberculosis, recurrent disease, management, Malawi

course chemotherapy* (2 months of pyrazinamide and ethambutol followed by isoniazid and ethambutol). If the patient had been treated with 'short-course' patient should be given the WHO management regimen (WHO, 1997). This could also be given to patients who were seriously ill, had extensive chest disease if this was the third episode of TB. In each hospital, adult patients had been registered with smear-negative and who were receiving the initial hospital were identified in either of wards. Registration details and treatment determined from TB-treatment cards. Patients were then questioned about whether they had had a previous episode of

17